• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The PLATO trial: Ticagrelor vs clopidogrel for ACS [Classics Series]

byAndrew Cheung, MD MBA
November 9, 2014
in Emergency Classics, General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with ticagrelor significantly reduces mortality in patients with acute coronary syndrome when compared to clopidogrel.

2. Ticagrelor does not significantly increase the incidence of major bleeding.

Original Date of Publication: September 2009

Study Rundown: Clopidogrel is a commonly used medication in the management of acute coronary syndromes (ACS). A previous study comparing prasugrel, another oral antiplatelet agent, with clopidogrel demonstrated a significant reduction in the risk of coronary thrombotic events, but no improvement in mortality. The Platelet Inhibition and Patient Outcomes (PLATO) trial compared the use of ticagrelor, a newer and more potent oral platelet inhibitor, with clopidogrel in treating patients with ACS. In summary, patients treated with ticagrelor experienced significantly lower rates of death from vascular causes, myocardial infarction, or stroke at 12 months when compared to patients on clopidogrel (HR 0.84; 95%CI 0.77-0.92). This was driven by both significant reductions in the rate of death from vascular causes and myocardial infarction. Moreover, there was no significant difference between the two groups in the rate of major bleeding (HR1.04; 95%CI 0.95-1.13).

Click to read study in NEJM

In-Depth [randomized, controlled study]: Originally published in 2009 in NEJM, this study was a multicenter trial, which randomized patients to treatment with clopidogrel or ticagrelor in addition to aspirin after ACS. Patients were eligible for the study if they were hospitalized for ACS with or without ST-segment elevation, with symptom onset in the previous 24 hours. Patients were excluded if they had contraindications to clopidogrel, they received fibrinolytic therapy in the 24 hours prior to randomization, they needed oral anticoagulation, they had an increased risk of bradycardia, or they were being treated with a strong cytochrome P-450 3A inhibitor or inducer. The primary endpoint was a composite of death from vascular causes, myocardial infarction, or stroke. Major life-threatening bleeding was defined as fatal bleeding, intracranial bleeding, intrapericardial bleeding with cardiac tamponade, shock/hypotension as a result of bleeding, hemoglobin decrease ≥5.0 g/dL, or need for transfusion of ≥4 units of packed red blood cells.

RELATED REPORTS

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting

#VisualAbstract: Ticagrelor monotherapy reduces bleeding risk following percutaneous coronary intervention

A total of 18,624 patients were recruited from 862 centres in 43 countries. At 12 months, the primary endpoint occurred significantly less in the ticagrelor group as compared with the clopidogrel group (HR 0.84; 95%CI 0.77-0.92). This difference was driven by significant reductions in rates of myocardial infarction (HR 0.84; 95%CI 0.75-0.95) and death from vascular causes (HR 0.79; 95%CI 0.69-0.91) in the ticagrelor group. The rates of major bleeding were not significantly different between the two groups (HR 1.04; 95%CI 0.95-1.13). Notably, the rate of fatal intracranial bleeding was significantly higher in the ticagrelor group compared to the clopidogrel group (p=0.02).

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: clopidogrelPLATOTicagrelor
Previous Post

HIV-infected infant potentially cured with antiretroviral therapy

Next Post

Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

RelatedReports

Stent type may not be related to adverse cardiac events after surgery
Cardiology

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

February 17, 2025
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting

September 25, 2024
#VisualAbstract: Ticagrelor monotherapy reduces bleeding risk following percutaneous coronary intervention
StudyGraphics

#VisualAbstract: Ticagrelor monotherapy reduces bleeding risk following percutaneous coronary intervention

June 3, 2024
Ultrasound enhances gastrointestinal absorption of drugs at low frequencies
Cardiology

Ticagrelor monotherapy reduces bleeding risk following percutaneous coronary intervention

May 22, 2024
Next Post
Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

CTA as an alternative to angiography for blunt cerebrovascular trauma detection

Decreased stroke incidence in high-income countries, decreased mortality worldwide (1990-2010)

Influenza vaccine associated with lower risk of major cardiovascular events

2 Minute Medicine Rewind October 20th – October 27th, 2013

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.